[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"ScreenCell\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":49},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":13,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":5},"100578146",false,"NCT06807502","Evaluation of Circulating Tumor Cells (CTC) Relevance in Breast Cancer Follow-up Using the ScreenCell Device","PROBE-CTC","INCLUSION CRITERIA\n\nFor all participants :\n\n* Female with age greater than or equal to 18 years\n\nFor participants with metastatic breast cancer:\n\n\\- Patient observed with metastatic breast cancer from the outset or metastatic fall from previously treated breast cancer with change of therapeutic line at the time of inclusion.\n\nFor participants with non-metastatic invasive breast cancer:\n\n\\- Patient observed with non-metastatic infiltrative breast cancer who had not received any treatment at the time of inclusion (naïve to any treatment)\n\nFor healthy volunteers:\n\n* Participant free of any cancer at the time of inclusion, confirmed using a mammogram whose results must be satisfactory, done at the latest two years before inclusion\n* Participant with no history of cancer\n\nEXCLUSION CRITERIA\n\nFor all participants:\n\n* Male\n* Age less than 18 years old\n* Refusal to participate or withdrawal of consent\n* Pregnant and\u002For breastfeeding women\n* Discovery of a cancerous pathology (other than breast cancer for patients) during participant follow-up.\n\nFor healthy volunteers:\n\n* History of cancer\n* Detection of CTC (positive profile) during screening",true,"FEMALE","18 Years",{"count":19,"type":20},93,"ESTIMATED","INTERVENTIONAL",[23],"NA","Liquid biopsy is a noninvasive method for detecting and quantifying circulating tumor cells (CTCs). Thanks to ScreenCell technology, this study aims to evaluate the evolution of the number of CTCs during breast cancer follow-up.\n\nThe identification and characterization of CTCs would make it possible to obtain information on the stage and molecular characteristics of cancer during follow-up",[26,27,28],"Breast Cancer, Metastatic","Breast Cancer Invasive","Breast Cancer Early Stage Breast Cancer (Stage 1-3)",[30,31,32,33,34,35,36],"CTC","Circulating Tumor Cells","Detection","Breast Cancer","Follow-up","Liquid Biopsy","Blood Test","RECRUITING","2026-04-21",{"date":40,"type":41},"2026-04-24","ACTUAL",{"date":43,"type":41},"2025-02-24",{"date":45,"type":20},"2026-11-30",{"name":47,"class":48},"ScreenCell","INDUSTRY",""]